Nektar Therapeutics Chief R&D Officer Sells Shares
| Reporter Name | Zalevsky Jonathan |
| Relationship | Chief R&D Officer |
| Type | Sell |
| Amount | $48,048 |
| SEC Filing | Form 4 |
Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, sold 51,115 shares of common stock on December 19, 2024, at a weighted average price of $0.94 per share, totaling $48,048. Following the transaction, Zalevsky directly owns 326,904 shares of the company.
SEC Filing: NEKTAR THERAPEUTICS [ NKTR ] - Form 4 - Dec. 20, 2024